Maria Vilarino-Varela

Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer

Gianmarco Leone, Francesco Orlando, Peter Dutey‐Magni, Osvaldas Vainauskas et autres

gb, it (code pays fourni par la source)

Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial

Chris Parker, Noel W. Clarke, Adrian Cook, Howard Kynaston et autres

gb, ca, dk (code pays fourni par la source)

Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol

Gerhardt Attard, Laura Murphy, Noel W. Clarke, Ashwin Sachdeva et autres

gb, ch (code pays fourni par la source)

Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial

Alison Tree, Peter Ostler, H. van der Voet, William Chu et autres

gb, ca, ie, us (code pays fourni par la source)

Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE) : a double-blind, randomised, phase 2 trial

Syed A. Hussain, J.F. Lester, Richard A. Jackson, Matthew Gornall et autres

gb, us (code pays fourni par la source)

Efficacy and Safety of Autologous Dendritic Cell–Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer

Nicholas J. Vogelzang, Tomasz M. Beer, Winald R. Gerritsen, Stéphane Oudard et autres

us, nl, fr, pl, cz, gb, de, rs, by, pt (code pays fourni par la source)

Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial

Douglas Brand, Alison Tree, Peter Ostler, H. van der Voet et autres

gb, ca (code pays fourni par la source)

VICTOR: Vinflunine in advanced metastatic transitional cell carcinoma of the urothelium (TCCU): a retrospective analysis of the use of vinflunine in multi-centre real life setting as second line chemotherapy through free of charge programme (FOCP) for patients in the UK and Ireland

Syed A. Hussain, Jawaher Ansari, Robert Huddart, Derek G. Power et autres

gb, ie (code pays fourni par la source)

2632 VICTOR: Vinflunine in advanced metastatic transitional cell carcinoma of the urothelium (TCCU): A retrospective analysis of the use of Vinflunine in a multi-centre real life setting as second line chemotherapy through the free of charge programme (FOCP) for patients in the UK

Sarah Talib Hussain, Rod Jackson, Seema Chauhan, Jawaher Ansari et autres

VICTOR: Vinflunine (Vin) in advanced metastatic transitional cell carcinoma of the urothelium (TCCU)—A retrospective analysis of use of Vin in multicenter, real life setting as second-line chemotherapy (ChT) through free-of charge-programme (FOCP) for patients (pts) in the UK.

Syed A. Hussain, Jawaher Ansari, Robert Huddart, James Wylie et autres

gb (code pays fourni par la source)

Benefits of online in vivo dosimetry for single-fraction total body irradiation

David Eaton, Alison Warry, Rachel E. Trimble, Maria Vilarino-Varela et autres

gb (code pays fourni par la source)

UP-02.162 Fiducial Markers for Image Localization Guidance in Prostate Gland Radiotherapy

AV Kaisary, K. Pigott, Maria Vilarino-Varela, N. Simpson et autres

gb (code pays fourni par la source)